Main Content
Molecular Biomarker
COPD represents a major medical challenge due to its great heterogeneity with multiple comorbid traits and diseases. Therefore, we carry out biologically-driven patient stratification based on polygenic risk scores to clinically define the relevance of different biomarkers (whole blood transcriptomics, extracellular vesicle surface proteomics, sputum microbiome) and to validate their correlation with the progression of the disease.
In our research project, we make use of existing clinical data to detect clinically relevant biomarkers and to validate them in a prospective, multi-center validation cohort. We take into account both technological feasibility as well as regulatory and commercial documentation and quality management standards to speed up technology transfer into translation and regulatory approval. The expertise we gain from these experiments aids in pre-preparatory work for the regulatory approval and clinical application that represent a major step towards a personalized medicine for COPD prevention and treatment.
People involved
Principle Investigators
Prof. Dr. Dominik Heider
Institute for Medical Informatics
Universität Münster
Prof. Dr. med. Bernd Schmeck
Institut für Lungenforschung
Philipps-Universität Marburg
Prof. Dr. med. Johnannes Schumacher
Institutfür Humangenetik
Philipps-Universität Marburg
Post-Doctoral Researchers
PD Dr. Wilhelm Goswin Bertrams
Institut für Lungenforschung
Philipps-Universität Marburg
Dr. Katrin Laakmann
Institut für Lungenforschung
Philipps-Universität Marburg
Dr. Roman Martin
Data Science in der Biomedizin
Philipps-Universität Marburg
Dr. Hendrik Pott
Institut für Lungenforschung
Philipps-Universität Marburg
Doctoral Researchers
Laura Köbbe, M. Sc.
Institut für Humangenetik
Philipps-Universität Marburg
Fatemeh Zarei
Institut für Lungenforschung
Philipps-Universität Marburg
IVD Advisor
Dr. Joachim Wienbeck
Principal Software Engineer
Myriad Genetics
